ERBB2 and breast carcinoma: Multivariable cox regression analysis suggested that the presence of at least one CD32B + B-CLS is an independent prognostic factor for shorter time to metastatic disease in patients with primary HER2 + breast cancer that received adjuvant trastuzumab, HR 4.2 [95%CI, (1.01–17.4)], p = 0.048 (Table 1).